Baseline clinical and angiographic data in the quinapril ischemic event (QUIET) Trial

The QUinapril Ischemic Event Trial (QUIET) is the first prospective, double-blind, placebo-controlled trial to investigate the long-term antiatherosclerotic effects of angiotensin-converting enzyme inhibition. Normotensive, nonhyperlipidemic subjects (1,750) with normal left ventricular systolic fun...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of cardiology Vol. 78; no. 9; pp. 1011 - 1016
Main Authors:	Lees, Robert S., Pitt, Bertram, Chan, Raymond C., Holmvang, Godtfred, Dinsmore, Robert E., Campbell, Lee W., Haber, Harry E., Klibaner, Michael I., Cashin-Hemphill, Linda, The QUIET Investigators
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-11-1996 Elsevier Elsevier Limited
Subjects:	Adult Aged Angioplasty Angioplasty, Balloon, Coronary Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antianginal agents. Coronary vasodilator agents Biological and medical sciences Cardiovascular disease Cardiovascular system Clinical trials Coronary Angiography Coronary Disease - blood Coronary Disease - diagnostic imaging Coronary Disease - drug therapy Coronary Disease - etiology Coronary Disease - therapy Coronary vessels Decision Trees Double-Blind Method Drug therapy Enzymes Female Humans Isoquinolines - pharmacology Isoquinolines - therapeutic use Lipids - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Quinapril Reproducibility of Results Smoking - adverse effects Tetrahydroisoquinolines Postoperative Human Quinapril Radiodiagnosis Enzyme Treatment efficiency Coronary artery Enzyme inhibitor Instrumentation therapy Cardiovascular disease Exploration Instrumental dilatation Coronary arteriography Coronary heart disease Peptidases Chemotherapy Treatment Peptidyl-dipeptidase A Follow up study Hydrolases Peptidyl-dipeptidases
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The QUinapril Ischemic Event Trial (QUIET) is the first prospective, double-blind, placebo-controlled trial to investigate the long-term antiatherosclerotic effects of angiotensin-converting enzyme inhibition. Normotensive, nonhyperlipidemic subjects (1,750) with normal left ventricular systolic function were randomly assigned to treatment or placebo at percutaneous transluminal coronary angioplasty (PTCA). The primary end point is time to first cardiac ischemic event. Baseline clinical characteristics are (mean ± SD): age 58 ± 9 years; blood pressure 123 ± 15 74 ± 10 mm Hg ; low density lipoprotein cholesterol 124 ± 27 mg/dL; high density lipoprotein cholesterol 37 ± 10 mg/dL; and triglycerides 167 ± 91 mg/dL. In addition, 81% are men; 22% are current smokers; 49% give a history of myocardial infarction. Baseline angiographic characteristics are (mean ± SD): left ventricular ejection fraction 59% ± 11%; per patient diameter stenosis (excluding the PTCA segment) 49% ±31%; 8.9 ± 3.5 analyzable segments per patient (excluding the PTCA segment), 3.8 ± 2.3 of which have visible stenosis. Including the PTCA segment, 52% have single vessel disease and 48% have multivessel disease. Baseline angiographic data for non-PTCA segments will be correlated with cardiac ischemic events which occur after 6 months. Up to 500 subjects will undergo followup angiography with quantitative coronary angiographic analysis (QCA) of baseline and follow-up films. The primary QCA end point will be per-patient categorical designation as progresser or nonprogressor based on the presence or absence of ≥400 μm narrowing in ≥ 1 vessels that did not undergo PTCA.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23
ISSN:	0002-9149 1879-1913
DOI:	10.1016/S0002-9149(96)00526-7